The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Eisenmenger's Syndrome Clinical Trial

Official title:

Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01283958
• Other study ID #: no sponsor
• Status: Completed
• Phase: N/A
• First received: January 25, 2011
• Last updated: January 25, 2011
• Start date: September 2007
• Est. completion date: May 2010

Study information

• Verified date: May 2010
• Source: Gachon University Gil Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion Criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Eisenmenger Complex
• Eisenmenger's Syndrome
• Heart Defects, Congenital
• Heart Diseases
• Syndrome

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gachon University Gil Medical Center